Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling

Jon E. Grant, Marc N. Potenza, Eric Hollander, Renee Cynningham-Williams, Tommi Nurminen, Gerard Smits, Antero Kallio

Research output: Contribution to journalArticle

201 Citations (Scopus)

Abstract

Objective: Pathological gambling is a disabling disorder experienced by approximately 1%-2% of adults and for which there are few empirically validated treatments. The authors examined the efficacy and tolerability of the opioid antagonist nalmefene in the treatment of adults with pathological gambling. Method: A 16-week, randomized, dose-ranging, double-blind, placebo-controlled trial was conducted at 15 outpatient treatment centers across the United States between March 2002 and April 2003. Two hundred seven persons with DSM-IV pathological gambling were randomly assigned to receive nalmefene (25 mg/day, 50 mg/day, or 100 mg/day) or placebo. Scores on the primary outcome measure (Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling) were analyzed by using a linear mixed-effects model. Results: Estimated regression coefficients showed that the 25 mg/day and 50 mg/day nalmefene groups had significantly different scores on the Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling, compared to the placebo group. A total of 59.2% of the subjects who received 25 mg/day of nalmefene were rated as "much improved" or "very much improved" at the last evaluation, compared to 34.0% of those who received placebo. Adverse experiences included nausea, dizziness, and insomnia. Conclusions: Subjects who received nalmefene had a statistically significant reduction in seventy of pathological gambling. Low-dose nalmefene (25 mg/day) appeared efficacious and was associated with few adverse events. Higher doses (50 mg/day and 100 mg/day) resulted in intolerable side effects.

Original languageEnglish (US)
Pages (from-to)303-312
Number of pages10
JournalAmerican Journal of Psychiatry
Volume163
Issue number2
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Gambling
Narcotic Antagonists
Placebos
Therapeutics
Sleep Initiation and Maintenance Disorders
Dizziness
Diagnostic and Statistical Manual of Mental Disorders
Nausea
nalmefene
Outpatients
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. / Grant, Jon E.; Potenza, Marc N.; Hollander, Eric; Cynningham-Williams, Renee; Nurminen, Tommi; Smits, Gerard; Kallio, Antero.

In: American Journal of Psychiatry, Vol. 163, No. 2, 02.2006, p. 303-312.

Research output: Contribution to journalArticle

Grant, Jon E. ; Potenza, Marc N. ; Hollander, Eric ; Cynningham-Williams, Renee ; Nurminen, Tommi ; Smits, Gerard ; Kallio, Antero. / Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. In: American Journal of Psychiatry. 2006 ; Vol. 163, No. 2. pp. 303-312.
@article{da15e60033134ff28a2374edb81906d9,
title = "Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling",
abstract = "Objective: Pathological gambling is a disabling disorder experienced by approximately 1{\%}-2{\%} of adults and for which there are few empirically validated treatments. The authors examined the efficacy and tolerability of the opioid antagonist nalmefene in the treatment of adults with pathological gambling. Method: A 16-week, randomized, dose-ranging, double-blind, placebo-controlled trial was conducted at 15 outpatient treatment centers across the United States between March 2002 and April 2003. Two hundred seven persons with DSM-IV pathological gambling were randomly assigned to receive nalmefene (25 mg/day, 50 mg/day, or 100 mg/day) or placebo. Scores on the primary outcome measure (Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling) were analyzed by using a linear mixed-effects model. Results: Estimated regression coefficients showed that the 25 mg/day and 50 mg/day nalmefene groups had significantly different scores on the Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling, compared to the placebo group. A total of 59.2{\%} of the subjects who received 25 mg/day of nalmefene were rated as {"}much improved{"} or {"}very much improved{"} at the last evaluation, compared to 34.0{\%} of those who received placebo. Adverse experiences included nausea, dizziness, and insomnia. Conclusions: Subjects who received nalmefene had a statistically significant reduction in seventy of pathological gambling. Low-dose nalmefene (25 mg/day) appeared efficacious and was associated with few adverse events. Higher doses (50 mg/day and 100 mg/day) resulted in intolerable side effects.",
author = "Grant, {Jon E.} and Potenza, {Marc N.} and Eric Hollander and Renee Cynningham-Williams and Tommi Nurminen and Gerard Smits and Antero Kallio",
year = "2006",
month = "2",
doi = "10.1176/appi.ajp.163.2.303",
language = "English (US)",
volume = "163",
pages = "303--312",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "2",

}

TY - JOUR

T1 - Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling

AU - Grant, Jon E.

AU - Potenza, Marc N.

AU - Hollander, Eric

AU - Cynningham-Williams, Renee

AU - Nurminen, Tommi

AU - Smits, Gerard

AU - Kallio, Antero

PY - 2006/2

Y1 - 2006/2

N2 - Objective: Pathological gambling is a disabling disorder experienced by approximately 1%-2% of adults and for which there are few empirically validated treatments. The authors examined the efficacy and tolerability of the opioid antagonist nalmefene in the treatment of adults with pathological gambling. Method: A 16-week, randomized, dose-ranging, double-blind, placebo-controlled trial was conducted at 15 outpatient treatment centers across the United States between March 2002 and April 2003. Two hundred seven persons with DSM-IV pathological gambling were randomly assigned to receive nalmefene (25 mg/day, 50 mg/day, or 100 mg/day) or placebo. Scores on the primary outcome measure (Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling) were analyzed by using a linear mixed-effects model. Results: Estimated regression coefficients showed that the 25 mg/day and 50 mg/day nalmefene groups had significantly different scores on the Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling, compared to the placebo group. A total of 59.2% of the subjects who received 25 mg/day of nalmefene were rated as "much improved" or "very much improved" at the last evaluation, compared to 34.0% of those who received placebo. Adverse experiences included nausea, dizziness, and insomnia. Conclusions: Subjects who received nalmefene had a statistically significant reduction in seventy of pathological gambling. Low-dose nalmefene (25 mg/day) appeared efficacious and was associated with few adverse events. Higher doses (50 mg/day and 100 mg/day) resulted in intolerable side effects.

AB - Objective: Pathological gambling is a disabling disorder experienced by approximately 1%-2% of adults and for which there are few empirically validated treatments. The authors examined the efficacy and tolerability of the opioid antagonist nalmefene in the treatment of adults with pathological gambling. Method: A 16-week, randomized, dose-ranging, double-blind, placebo-controlled trial was conducted at 15 outpatient treatment centers across the United States between March 2002 and April 2003. Two hundred seven persons with DSM-IV pathological gambling were randomly assigned to receive nalmefene (25 mg/day, 50 mg/day, or 100 mg/day) or placebo. Scores on the primary outcome measure (Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling) were analyzed by using a linear mixed-effects model. Results: Estimated regression coefficients showed that the 25 mg/day and 50 mg/day nalmefene groups had significantly different scores on the Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling, compared to the placebo group. A total of 59.2% of the subjects who received 25 mg/day of nalmefene were rated as "much improved" or "very much improved" at the last evaluation, compared to 34.0% of those who received placebo. Adverse experiences included nausea, dizziness, and insomnia. Conclusions: Subjects who received nalmefene had a statistically significant reduction in seventy of pathological gambling. Low-dose nalmefene (25 mg/day) appeared efficacious and was associated with few adverse events. Higher doses (50 mg/day and 100 mg/day) resulted in intolerable side effects.

UR - http://www.scopus.com/inward/record.url?scp=33645007938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645007938&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.163.2.303

DO - 10.1176/appi.ajp.163.2.303

M3 - Article

VL - 163

SP - 303

EP - 312

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 2

ER -